亚太子宫腺肌病药物市场 – 行业趋势和 2030 年预测

亚太子宫腺肌病药物市场分析及规模

子宫腺肌病是一种良性子宫疾病，病理上表现为子宫内膜腺体和基质位于子宫肌层内。患有子宫腺肌病的女性可能出现异常子宫出血 (AUB)、痛经、性交困难或不孕，但其中三分之一没有症状。多年来，子宫腺肌病一直是围绝经期女性在子宫切除术后出现的月经过多 (HMB) 或盆腔痛的组织病理学诊断。然而，由于近年来成像技术的进步，子宫腺肌病在过去十年中也成为年轻育龄女性中发现的一种疾病，尽管仍然缺乏共同的定义和分类。尽管诊断工具有所改进，但对该疾病的认识仍然很差。

Data Bridge Market Research 分析，亚太地区子宫腺肌病药物市场在 2022 年为 237 万美元，预计到 2030 年将达到 395 万美元，在 2023 年至 2030 年的预测期内，复合年增长率可能达到 6.6%。“抗炎药物”在子宫腺肌病药物市场的治疗领域占据主导地位，因为用于治疗子宫腺肌病的药物通常包括抗炎药物。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

亚太子宫腺肌病药物市场范围和细分

Market Definition

Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.

Global Adenomyosis Drugs Market Dynamics

Drivers

• Increasing Prevalence of Adenomyosis

The rising incidence and prevalence of adenomyosis in the Asia-Pacific region is a significant driver for the market. Adenomyosis is a common gynecological disorder among women, and as awareness grows and diagnostic capabilities improve, more cases are being identified and treated. This drives the demand for adenomyosis drugs.

• Advancements in Medical Technology

Advances in medical technology, including improved diagnostic methods and minimally invasive surgical techniques, are leading to earlier and more accurate diagnoses of adenomyosis. This, in turn, is driving the demand for drugs that can effectively manage the condition, as patients and healthcare providers seek less invasive treatment options.

• Aging Population 

The aging population in the Asia-Pacific region is contributing to the growth of adenomyosis cases. Older women are at a higher risk of developing adenomyosis, and as the population ages, the demand for drugs to manage the condition is likely to increase.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Advancements in Research and Development

Ongoing research in the field of gynecology and women's health is leading to the development of new and more effective drugs for adenomyosis. Pharmaceutical companies can capitalize on these advancements by introducing innovative treatment options that provide better outcomes and fewer side effects, which can differentiate their products in the market.

• Telemedicine and Digital Health Solutions

The adoption of telemedicine and digital health solutions in the Asia-Pacific region is on the rise, especially in the wake of the COVID-19 pandemic. This presents an opportunity for healthcare providers and pharmaceutical companies to reach and educate patients about adenomyosis treatments remotely, improving access to healthcare services and medications.

Restraints/Challenges

• Limited Awareness and Diagnosis

Adenomyosis is often underdiagnosed or misdiagnosed as other gynecological conditions, leading to delayed or incorrect treatment. Limited awareness among both patients and healthcare providers can hinder the market's growth, as early diagnosis and treatment are crucial for effective management.

• High Treatment Costs

The cost of adenomyosis drugs and treatments can be a significant barrier, especially in countries with lower healthcare budgets and a large proportion of out-of-pocket healthcare expenses. High treatment costs may limit access to effective therapies for many patients.

• Underdiagnosis and Misdiagnosis

Adenomyosis is often underdiagnosed or misdiagnosed as other gynecological conditions, such as endometriosis or fibroids. Accurate diagnosis can be challenging, and this delay or misdiagnosis can hinder the timely initiation of appropriate treatment. Addressing this challenge requires increased awareness and improved diagnostic methods.

• Limited Treatment Options

Currently, there are limited specific drugs approved for the treatment of adenomyosis. Most treatment approaches involve managing symptoms, such as pain and heavy menstrual bleeding, rather than directly targeting the underlying condition. The lack of dedicated medications for adenomyosis can be a significant challenge for patients and healthcare providers seeking effective treatments.

本子宫腺肌病药物市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩张、市场技术创新。如需了解有关子宫腺肌病药物市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

最新动态

• 2021年10月，总部位于瑞士的亚太生物制药公司Debiopharm与印度尼西亚领先的制药公司Dexa Medica宣布在印度尼西亚推出曲普瑞林，用于治疗患有妇科疾病（特别是子宫腺肌病）及其相关疾病的女性
• 2019 年 9 月，昆士兰大学和莫纳什 IVF 的 Caroline Gargett 教授及其同事获得了一项为期三年、价值 207 万美元（305 万澳元）的资助，用于确定子宫腺肌病的病因以及与该疾病相关的生理过程

亚太子宫腺肌病药物市场范围

子宫腺肌病药物市场根据类型、治疗、患者类型、剂型、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• 扩散
• 结节性
• 硬化
• 成人囊性
• 其他的

治疗

• 激素药物
• 抗炎药物
• 其他的

患者类型

• 青春期
• 成人
• 老年

剂型

• 肠外
• 口服
• 其他的

终端用户

• 医院
• 诊所
• 专业中心
• 家庭医疗保健
• 流动中心
• 其他的

 分销渠道

• 医院药房 
• 零售药店
• 网上药店
• 其他的

亚太子宫腺肌病药物市场区域分析/见解

对子宫腺肌病药物市场进行了分析，并按类型、治疗、患者类型、剂型、分销渠道和最终用户提供了市场规模洞察和趋势。

子宫腺肌病药物市场报告涵盖的国家包括日本、中国、印度、澳大利亚、新加坡、韩国、马来西亚、泰国、印度尼西亚、菲律宾、越南和亚太地区其他地区。

由于该疾病的发病率和诊断率的增加，预计日本将在预测期内主导亚太市场。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和亚太子宫腺肌病药物市场份额分析

子宫腺肌病药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对子宫腺肌病药物市场的关注有关。

子宫腺肌病药物市场的一些主要参与者包括：

• Mayne Pharma Group Limited（澳大利亚）
• Accord Healthcare（英国）
• 勃林格殷格翰国际有限公司 (德国)
• Ferring BV（瑞士）
• Par Pharmaceutical（Endo International plc 的子公司）（美国）
• Hikma Pharmaceuticals PLC（英国）
• Viatris Inc.（美国）
• 拜耳公司（德国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 阿斯利康（英国）
• 辉瑞公司（美国）
• 太阳制药工业有限公司 (印度)
• AbbVie Inc.（美国）
• 雅培（美国）
• 葛兰素史克公司（英国）
• 诺华公司（瑞士）
• Amneal Pharmaceuticals LLC（美国）
• 强生服务公司（美国）
• 赛诺菲（法国）
• Dr. Reddy's Laboratories Ltd.（印度）

SKU-68392